BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the company has initiated a phase II clinical trial of SGN-40 for the treatment of patients with diffuse large B-cell lymphoma, the most common type of aggressive non-Hodgkin’s lymphoma (NHL).
